Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6876939 | 0.82 | ALDH1A1 (0.37) | KDM4EALDH1A1LMNA | |
| SCHEMBL6876943 | 0.82 | ALDH1A1 (0.37) | KDM4EALDH1A1LMNA | |
| SCHEMBL31262606 | 0.80 | KDM4B (0.33) | CYP2A6 | |
| SCHEMBL6851830 | 0.79 | KDM4E (0.48) | KDM4EALDH1A1SMN1; SMN2LMNAHDAC1 | |
| SCHEMBL6851976 | 0.78 | CYP19A1 (0.32) | CYP19A1 | |
| SCHEMBL6852841 | 0.74 | — | — | |
| SCHEMBL6852901 | 0.74 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL6852836 | 0.74 | — | — | |
| SCHEMBL6852906 | 0.74 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL28755646 | 0.73 | ERN1 (0.40) | LMNAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1585775-A | 6-O-acyl ketolide derivatives of erythromycine useful as antibacterials | ORTHO MCNEIL PHARM INC (US) | 2005-02-23 | — | — | CN | disclosed |
| US-6825170-B2 | ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-11-30 | — | — | US | disclosed |
| EP-1453847-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003050132-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | Q6ZSR9, ACSL6, RPS4Y1 | KDM4E 18/4885ALDH1A1 2109/4885SMN1; SMN2 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.